Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | TERT | O14746 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | XBP1 | P17861 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8601755 | 0.98 | KCNH2 (0.42) | KCNH2TERTHSD17B10KDM4EALDH1A1 | |
| SCHEMBL9438134 | 0.98 | KCNH2 (0.42) | KCNH2TERTHSD17B10KDM4EALDH1A1 | |
| SCHEMBL433614 | 0.98 | KCNH2 (0.42) | KCNH2TERTHSD17B10KDM4EALDH1A1 | |
| SCHEMBL15468129 | 0.98 | KCNH2 (0.42) | KCNH2TERTHSD17B10KDM4EALDH1A1 | |
| SCHEMBL3475623 | 0.95 | MAPT (0.41) | TERTHSD17B10KDM4EALDH1A1HPGD | |
| SCHEMBL6003423 | 0.91 | TERT (0.34) | KCNH2TERTHSD17B10KDM4EALDH1A1 | |
| SCHEMBL7262879 | 0.91 | TERT (0.34) | KCNH2TERTHSD17B10KDM4EALDH1A1 | |
| SCHEMBL6003452 | 0.89 | KCNH2 (0.36) | KCNH2TERTHSD17B10KDM4EALDH1A1 | |
| SCHEMBL6003931 | 0.89 | TERT (0.33) | KCNH2TERTHSD17B10KDM4EALDH1A1 | |
| SCHEMBL17419216 | 0.89 | KCNH2 (0.36) | KCNH2TERTHSD17B10KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009103821-A2 | MEANS FOR TREATING VIRUS INFECTIONS | VIROLOGIK GMBH (DE) | 2009-08-27 | — | — | WO | claimed |
| US-6730666-B1 | INHIBITION OF GROWTH FACTOR TYROSINE KINASE RECEPTOR ACTIVITY, PARTICULARLY INHIBITION OF ANGIOGENESIS AND RELATED DISORDERS, TUMOR PROGRESSION AND GROWTH FACTOR RELATED SKELETAL DISORDERS, BY PORPHYRIN AND CORROLE COMPOUNDS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2004-05-04 | — | — | US | claimed |
| WO-2002089779-A2 | COMBINED PREPARATION FOR THE PROPHYLAXIS AND/OR THERAPY OF NERVE CELL AND/OR GLIA CELL DAMAGE USING A NOVEL METHOD OF TREATMENT | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH (DE) | 2002-11-14 | — | — | WO | claimed |
| CN-115057873-A | 5,10,15, 20-tetra (pentafluorophenyl) -2, 3-benzothiazole fused chlorophyll compound and preparation method thereof | 湖南科技大学 | 2022-09-16 | — | — | CN | disclosed |
| US-20140303182-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | NOVARTIS AG (CH) | 2014-10-09 | — | — | US | disclosed |
| EP-2772257-A1 | Formulations of quinolinones | Novartis AG (CH) | 2014-09-03 | — | — | EP | disclosed |
| EP-2762475-A1 | Pharmaceutically acceptable salts of quinolinone compounds and their medical use | Novartis Vaccines and Diagnostics, Inc. (US) | 2014-08-06 | — | — | EP | disclosed |
| EP-2465857-B1 | Methods for synthesizing heterocyclic compounds | NOVARTIS AG (CH) | 2014-06-04 | — | — | EP | disclosed |
| EP-1699421-B1 | Lactate salts of quinolinone compounds and their pharmaceutical use | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2014-05-21 | — | — | EP | disclosed |
| EP-1957074-B1 | FORMULATIONS OF QUINOLINONES | NOVARTIS AG (CH) | 2014-03-19 | — | — | EP | disclosed |
| US-20130338171-A1 | Pharmaceutically Acceptable Salts of Quinolinone Compounds Having Improved Pharmaceutical Properties | NOVARTIS AG (CH) | 2013-12-19 | — | — | US | disclosed |
| US-20020107392-A1 | Quinolinone derivatives | NOVARTIS AG (CH) | 2002-08-08 | — | — | US | disclosed |
| US-20020103230-A1 | Heterocyclic compounds | CHIRON CORPORATION | 2002-08-01 | — | — | US | disclosed |
| WO-2002022598-A1 | QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2002-03-21 | — | — | WO | disclosed |
| WO-2002018383-A2 | AZA HETEROCYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE | CHIRON CORPORATION (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-2000027379-A3 | Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives | YEDA RES & DEV (IL) | 2001-08-23 | — | — | WO | disclosed |
| EP-1002020-A1 | DYE INTERMEDIATE AND METHOD TO MANUFACTURE DYES | Nycomed Amersham plc (GB) | 2000-05-24 | — | — | EP | disclosed |
| WO-2000027379-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING PORPHYRINS AND SOME NOVEL PORPHYRIN DERIVATIVES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2000-05-18 | — | — | WO | disclosed |
| WO-2000027379-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING PORPHYRINS AND SOME NOVEL PORPHYRIN DERIVATIVES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2000-05-18 | — | — | WO | disclosed |
| WO-1999007793-A1 | DYE INTERMEDIATE AND METHOD TO MANUFACTURE DYES | NYCOMED AMERSHAM PLC (GB) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103230-A1 | Heterocyclic compounds | SLCO2A1, SLCO1B1, SLCO2B1 | KCNH2 476/4885TERT 2139/4885HSD17B10 793/4885 |
| US-20130338171-A1 | Pharmaceutically Acceptable Salts of Quinolinone Compounds Having Improved Pharmaceutical Properties | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | KCNH2 1043/4885TERT 3371/4885HSD17B10 1495/4885 |
| US-20020107392-A1 | Quinolinone derivatives | SLCO1B1, SLCO1B3, SLCO1A2 | KCNH2 773/4885TERT 3311/4885HSD17B10 540/4885 |
| US-20140303182-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | KCNH2 1043/4885TERT 3371/4885HSD17B10 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.